CardieX’s subsidiary ATCOR Medical has commenced a new 2,000-hypertensive patient study to identify care outcomes linked with the regular monitoring of central aortic blood pressure (cBP) and peripheral blood pressure (pBP).
This longitudinal study, which is based on more than six years of patient data, will analyse the effects of routine monitoring of patients with elevated blood pressure on medication prescriptions and patient well-being.
The company’s SphygmoCor vascular biomarker technology will be used for the study.
CardieX CEO Craig Cooper said: “Retrospective studies have always been an important focus for ATCOR.
“Our hope is that the data from this study will definitively show how routine blood pressure monitoring using novel digital vascular biomarkers can improve health outcomes and advance the field of cardiovascular medicine.”
Retrospective studies can help improve patient-centric vascular health management and offer a better understanding of the influence of gender, race and other factors on vascular risk.
Currently, ATCOR is building an outcome-based vascular health database that will track the impact of interventional therapies on digital vascular biomarkers in various populations.
The company is working with Adaptive Clinical Systems to aggregate longitudinal data from medical imaging, electronic health records, SphygmoCor digital biomarker data and other sources.
ATCOR Medical president Toni Hofhine said: “This study will no doubt deepen our understanding of vascular health risk factors in the management of chronic disease.”
Using SphygmoCor central blood pressure technology, the company develops medical devices for hypertension, cardiovascular disease and other vascular health disorders.